REGISTER NOW THE SKIN ISSUE FOR CCR 2024 June 2024 | VOLUME 11 - ISSUE 7
The Resource for Medical Aesthetic Professionals
This content is intended for UK and Irish HCPs only.
The Allergan Aesthetics Portfolio 1–10
A valuable partner Help address some of your patients’ skin quality concerns with a multimodal treatment approach.1,10-14*†
Produced and funded by Allergan Aesthetics, an AbbVie company.
UK-AGNA-240171 | May 2024
References: * Such treatment decisions must be assessed and discussed as part of the healthcare professional–patient consultation prior to any treatment being administered. † Multimodal aesthetics treatment describes the use of more than one type of treatment modality that are administered as part of a patient’s treatment plan.
By scanning the QR code, you are being directed to a third party website on which Allergan Aesthetics, an Abbvie company are only responsible for the references for this article.
Models have been treated with Allergan Aesthetics product. Individual results may vary. The safety and efficacy of HArmonyCa™ has not been evaluated in patients treated with other filling implants.10 There is no data available regarding the safety of injecting a greater amount than 20mL of ALLERGAN dermal fillers per 60kg body mass per year.4 HArmonyCa™ Lidocaine is referred to as HArmonyCa™. ©2024 AbbVie. All rights reserved. All trademarks are the property of their respective owners.
Adverse events should be reported. UK reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available at Google Play or Apple App stores. Adverse events should also be reported to AbbVie on ProductSurveillance_EAME@allergan.com. Irish HCPs are asked to report any suspected adverse reactions via HPRA Pharmacovigilance; website: www.hpra.ie.
CPD: Polynucleotides for Hair Loss Dr Edward Robinson explores the literature around polynucleotide use for hair loss
Special Feature: Examining Treatment Approaches to Manage Scars Treating Melasma: Discussing Various Treatment Modalities for Melasma
ALSO IN THIS ISSUE
Dr Nicole Chiang provides an overview of common facial dermatoses CCR 2024 marks its return with the latest advancements in medical aesthetics